Belite Bio (NASDAQ:BLTE) Stock Price Target Raised at Canaccord Genuity Group

Belite Bio (NASDAQ:BLTE – Get Free Report) had its price target boosted by investment analysts at Canaccord Genuity Group from $303.00 to $314.00 in a research note issued on Monday, Benzinga reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity Group‘s price objective points to a potential upside of 92.86% from the stock’s previous close.

A number of other equities research analysts have also issued reports on BLTE. Leerink Partners lifted their target price on shares of Belite Bio from $185.00 to $215.00 and gave the company an “outperform” rating in a research note on Friday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Belite Bio in a research report on Friday, October 2nd. HC Wainwright restated a “buy” rating and issued a $245.00 target price on shares of Belite Bio in a research note on Thursday, October 15th. Benchmark restated a “buy” rating on shares of Belite Bio in a research report on Friday, August 14th. Finally, Zacks Research lowered shares of Belite Bio from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 18th. Nine analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $226.91.

Get Our Latest Stock Analysis on BLTE

Belite Bio Stock Performance

Shares of NASDAQ BLTE traded down $1.54 during trading on Monday, reaching $162.81. The stock had a trading volume of 134,608 shares, compared to its average volume of 190,552. Belite Bio has a one year low of $105.88 and a one year high of $200.00. The stock has a market cap of $6.56 billion, a PE ratio of -59.96 and a beta of -1.19. The firm’s 50 day moving average price is $160.88 and its two-hundred day moving average price is $160.24.

Belite Bio (NASDAQ:BLTE – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.19. On average, research analysts expect that Belite Bio will post -3.08 earnings per share for the current year.

Insider Activity

In other Belite Bio news, CEO Yu-Hsin Lin sold 26,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $196.56, for a total transaction of $5,110,560.00. Following the completion of the transaction, the chief executive officer directly owned 70,134 shares in the company, valued at $13,785,539.04. The trade was a 27.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Hao-Yuan Chuang sold 17,962 shares of the company’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $196.42, for a total value of $3,528,096.04. Following the sale, the chief financial officer owned 26,038 shares of the company’s stock, valued at approximately $5,114,383.96. This represents a 40.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 168,330 shares of company stock worth $31,969,118. 13.29% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Belite Bio

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Affinity Asset Advisors LLC raised its position in shares of Belite Bio by 225.0% during the first quarter. Affinity Asset Advisors LLC now owns 65,000 shares of the company’s stock worth $10,364,000 after acquiring an additional 45,000 shares during the last quarter. Candriam S.C.A. acquired a new stake in Belite Bio during the 3rd quarter valued at approximately $10,711,000. The Manufacturers Life Insurance Company acquired a new stake in Belite Bio during the 1st quarter valued at approximately $3,125,000. Renaissance Technologies LLC bought a new position in Belite Bio during the 1st quarter worth approximately $8,291,000. Finally, Amundi acquired a new position in shares of Belite Bio in the 1st quarter worth approximately $671,000. 0.53% of the stock is currently owned by institutional investors and hedge funds.

About Belite Bio

(Get Free Report)

Belite Bio, Inc. is a clinical-stage biopharmaceutical company developing treatments for retinal and metabolic diseases. The company focuses on conditions with limited treatment options, including inherited retinal disorders and age-related eye disease. Its lead drug candidate, tinlarebant, is an oral therapy designed to reduce the accumulation of toxic vitamin A byproducts in the retina. Belite Bio is evaluating tinlarebant for Stargardt disease and geographic atrophy associated with dry age-related macular degeneration.

Further Reading

Analyst Recommendations for Belite Bio (NASDAQ:BLTE)

Receive News & Ratings for Belite Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Belite Bio and related companies with MarketBeat.com's FREE daily email newsletter.